Get the Stockscreener App
129.41
1.67%
2.13
After Hours:
129.41
Insmed Inc stock is traded at $129.41, with a volume of 1.70M.
It is up +1.67% in the last 24 hours and down -2.38% over the past month.
Insmed Inc is a biopharmaceutical company. Its commercial portfolio and clinical pipeline are organized around three therapeutic areas: Respiratory, Immunology and Inflammation, and Neuro and Other Rare. The company's two commercial products, Arikayce and Brinsupri, are both part of the Respiratory therapeutic area. The firm's clinical-stage programs are TPIP, INS1148, brensocatib, and INS1201, focusing on different therapeutic areas. Additionally, Insmed's pre-clinical research programs encompass various technologies and modalities, including gene therapy, AI-driven protein engineering, protein manufacturing, RNA end-joining, and synthetic rescue. Geographically, the company generates maximum revenue from the United States from the sale of its commercial products.
See More
Previous Close:
$127.28
Open:
$127.98
24h Volume:
1.70M
Relative Volume:
0.53
Market Cap:
$28.26B
Revenue:
$819.56M
Net Income/Loss:
$-1.18B
P/E Ratio:
-22.53
EPS:
-5.7434
Net Cash Flow:
$-951.64M
1W Performance:
+2.47%
1M Performance:
-2.38%
6M Performance:
-7.17%
1Y Performance:
-11.23%
1-Day Range:
$126.52
$130.25
1-Week Range:
$121.03
$130.83
52-Week Range:
$90.39
$212.75
Insmed Inc Stock (INSM) Company Profile
Name
Insmed Inc
Sector
Industry
Phone
908-977-9900
Address
700 US HIGHWAY 202/206, BRIDGEWATER, NJ
Compare INSM vs VRTX, REGN, ARGX, MRNA, RVMD
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
INSM
Insmed Inc
|
129.41 | 28.26B | 819.56M | -1.18B | -951.64M | -5.7434 |
VRTX
Vertex Pharmaceuticals Inc
|
515.44 | 130.64B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
781.49 | 80.46B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
984.39 | 61.58B | 4.16B | 1.29B | 734.26M | 19.58 |
MRNA
Moderna Inc
|
143.97 | 57.48B | 2.23B | -3.19B | -1.60B | -8.1462 |
RVMD
Revolution Medicines Inc
|
203.77 | 43.68B | 742.00K | -1.37B | -1.07B | -7.0731 |
Insmed Inc Stock (INSM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Apr-10-26 | Initiated | Raymond James | Outperform |
| Mar-30-26 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Mar-16-26 | Resumed | Jefferies | Buy |
| Jan-28-26 | Initiated | Barclays | Overweight |
| Jan-23-26 | Initiated | Roth Capital | Buy |
| Dec-19-25 | Resumed | Truist | Buy |
| Dec-04-25 | Initiated | Rothschild & Co Redburn | Buy |
| Oct-28-25 | Resumed | Cantor Fitzgerald | Overweight |
| Oct-20-25 | Initiated | Wells Fargo | Overweight |
| Aug-20-25 | Initiated | William Blair | Outperform |
| Aug-13-25 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| May-13-25 | Initiated | Jefferies | Buy |
| Feb-25-25 | Initiated | RBC Capital Mkts | Outperform |
| Apr-23-24 | Initiated | Truist | Buy |
| Feb-15-24 | Initiated | Wolfe Research | Outperform |
| Dec-08-23 | Initiated | Wells Fargo | Overweight |
| Nov-20-23 | Resumed | JP Morgan | Overweight |
| Jul-26-23 | Initiated | Guggenheim | Buy |
| Dec-09-22 | Initiated | Mizuho | Buy |
| Dec-07-22 | Initiated | Barclays | Overweight |
| Nov-18-22 | Initiated | BofA Securities | Buy |
| Apr-27-22 | Initiated | Goldman | Buy |
| Dec-06-21 | Initiated | JP Morgan | Overweight |
| Oct-19-21 | Resumed | Monness Crespi & Hardt | Buy |
| Oct-19-21 | Resumed | Morgan Stanley | Overweight |
| Oct-08-21 | Initiated | Cantor Fitzgerald | Overweight |
| Apr-26-21 | Resumed | Credit Suisse | Outperform |
| Dec-17-20 | Initiated | Berenberg | Buy |
| Oct-12-20 | Resumed | Stifel | Buy |
| Sep-03-19 | Initiated | Goldman | Buy |
| Apr-09-19 | Reiterated | H.C. Wainwright | Buy |
| Feb-15-19 | Upgrade | JMP Securities | Mkt Perform → Mkt Outperform |
| Jan-17-19 | Upgrade | Goldman | Neutral → Buy |
| Jan-02-19 | Initiated | Canaccord Genuity | Buy |
| Aug-06-18 | Downgrade | JMP Securities | Mkt Outperform → Mkt Perform |
| Jul-23-18 | Initiated | Goldman | Neutral |
| Apr-23-18 | Upgrade | Credit Suisse | Neutral → Outperform |
| Mar-21-18 | Initiated | Morgan Stanley | Overweight |
| Jan-18-18 | Initiated | Credit Suisse | Neutral |
| Sep-05-17 | Reiterated | Evercore ISI | Outperform |
| Aug-17-17 | Initiated | Evercore ISI | Outperform |
| Jul-11-17 | Initiated | Robert W. Baird | Outperform |
| Mar-15-16 | Initiated | Stifel | Buy |
| Nov-09-15 | Downgrade | UBS | Buy → Neutral |
| Oct-06-15 | Reiterated | H.C. Wainwright | Buy |
| Jun-09-15 | Initiated | Citigroup | Neutral |
| Mar-26-14 | Reiterated | HC Wainwright | Buy |
View All
Insmed Inc Stock (INSM) Latest News
Insmed(INSM.US) Director Sells US$3.1 Million in Common Stock - Moomoo
Insmed Director Sold Shares Worth Over $3.1M - TradingView
Insmed (INSM) director sells 25,000 shares in open-market deal - Stock Titan
LQDA Loses 13.9% in a Month: Should Investors Avoid the Stock Now? - Zacks Investment Research
Insmed (NASDAQ: INSM) director lines up 25,000-share sale - Stock Titan
Exiting Insmed (INSM) Following Disappointing Key Drug Uptake - Yahoo Finance
INSM, FSLR, APTV: Dreaded Death Cross Has Formed On These Stocks — What It Means For Investors - Stocktwits
Can Insmed (INSM) Still Look Reasonable After Raised Sales Guidance? - webull.com
Insmed Incorporated at Cantor Global Healthcare Conference Transcript - GuruFocus
Insmed at Cantor conference: higher sales outlook lifts growth case By Investing.com - Investing.com Australia
Why Insmed (INSM) Stock Is Up Today - Quiver Quantitative
Insmed’s New Lung Disease Study Data A Win For Company, Says Analyst - Stocktwits
Insmed rated Strong Buy with 39% upside on robu... - Pluang
Here's How Much $100 Invested In Insmed 5 Years Ago Would Be Worth Today - Benzinga
Insmed Stock Price Forecast. Should You Buy INSM? - StockInvest.us
Insmed to Present Data across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - marketscreener.com
Insmed Grants Inducement Awards to 128 New Employees - Intellectia AI
128 new employees receive stock awards from Insmed - Stock Titan
INSM Looks 38.8% Undervalued on GF Value™ Despite Profitability Challenges - GuruFocus
Insmed presents new respiratory drug data at ER... - Pluang
Insmed to Present Data Across Its Respiratory Portfolio, Including New Late-Breaking ARIKAYCE® (amikacin liposome inhalation suspension) Results From Phase 3b ENCORE Study at the European Respiratory Society Congress 2026 - PR Newswire
The top 12 companies hiring in biopharma now - BioSpace
Insmed director Sharoky sells $637,650 of Insmed stock By Investing.com - Investing.com Nigeria
Insmed director Sharoky sells $637,650 of Insmed stock - Investing.com
Do You Believe in Insmed’s INSM) Long-Term Potential Despite Short-Term Challenges? - Yahoo Finance
Insmed’s (INSM) New Drug Launch Is Reshaping The Whole Business - Yahoo Finance
Insmed Incorporated (INSM): Investor Outlook on a Biotech Pioneer with 68.87% Potential Upside - DirectorsTalk Interviews
If You Invested $1000 In Insmed Stock 10 Years Ago, You Would Have This Much Today - Benzinga
Insmed (INSM) Q1 2025 Earnings: Results, Market Reaction & History - 24/7 Wall St.
Liquidia vs. Insmed: Which Pulmonary Stock Has Better Prospects Now? - TradingView
Insmed will speak at two New York healthcare conferences in September - Stock Titan
Insmed to Present at September 2026 Investor Conferences - PR Newswire
Insmed director Melvin Sharoky sells $637,650 in shares - Investing.com
Japan approves the first treatment for a chronic lung disease that can damage lungs - Stock Titan
Insmed (INSM) Q2 2026 Earnings Call Transcript - AOL.com
Biotech Is Booming, But These 2 Stocks Missed the Memo - Sahm
Insmed Slides 4.3% as Recent Insider Sales and Post-Earnings Profit-Taking Weigh on Shares - Quiver Quantitative
Insmed Director Melvin Sharoky Reports Sale of 5,000 Shares via Padonia, LLC - Kalkine Media
Insmed Insider Sold Shares Worth $637,650, According to a Recent SEC Filing - marketscreener.com
Insmed (NASDAQ: INSM) director sells 5,000 shares via Padonia LLC - Stock Titan
How Insmed’s Sharply Narrowed Q2 2026 Net Loss At Insmed (INSM) Has Changed Its Investment Story - simplywall.st
BMO Capital Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $192 - Moomoo
Insmed (NASDAQ: INSM) holder Padonia targets $638K share sale - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Insmed CMO Martina Flammer sells $3.49m in company stock By Investing.com - Investing.com Australia
Insmed CMO Martina Flammer sells $3.49m in company stock - Investing.com
H.C. Wainwright Maintains Insmed(INSM.US) With Buy Rating, Maintains Target Price $220 - Moomoo
13,000 Shares in Insmed, Inc. $INSM Purchased by S&CO Inc. - MarketBeat
Insmed, Inc. $INSM Shares Bought by Empowered Funds LLC - MarketBeat
Darwin Global updates Insmed Inc (INSM) ownership, reporting 3.0% beneficial stake - Stock Titan
Insmed(INSM.US) Officer Sells US$31.96 Million in Common Stock - moomoo.com
Insmed Inc Stock (INSM) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.29%
0.47%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):